MedTrace Logo

Vancomycin Versus Ceftaroline in Patients With Infections Caused by MRSA That Are Susceptible to Ceftaroline

NCT01724671 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2012-11-12

No results posted yet for this study

Summary

To compare the time to pathogen eradication, and the relationship to the time to clinical improvement, between ceftaroline and case-matched vancomycin treated controls in the treatment of adults with serious infections caused by Methicillin-Resistant Staphylococcus aureus (MRSA).

Conditions

Sponsors & Collaborators

  • Forest Laboratories

    collaborator INDUSTRY

  • CPL Associates

    lead OTHER

Principal Investigators

  • Jerome J Schentag, Pharm.D. · State University at Buffalo

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01724671 on ClinicalTrials.gov